2026-09-14T13:02:47Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/276982026-09-11T15:36:34Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Iglesias-Caballero, Maria author Mas-Lloret, Vicente author Campoy, Albert author Calvo, Cristina author García, María Luz author Alcolea, Sonia author Moreno-Parrado, Laura author Reina, Jordi author Navascués, Ana author Antón, Andrés author Davina-Nunez, Carlos author Perez-Castro, Sonia author Costa, José author Fernández-González, Ana author Lepe, José Antonio author Gaona, Cristina author Pérez, Zulema author García-Martínez de Artola, Diego author Vázquez-Morón, Sonia author Camarero-Serrano, Sara author Cano, Olga author Pozo Sanchez, Francisco author Casas Flecha, Inmaculada author 2026-02-18 Respiratory Syncytial Virus (RSV) is a leading cause of respiratory infections in infants and older adults. In Spain, surveillance is supported by the SiVIRA system and the RELECOV genomic sequencing network. The 2023-2024 season marked the first nationwide administration of nirsevimab, a monoclonal antibody for preventing severe RSV in infants. This study analyzes the genomic evolution of RSV during this period, focusing on potential escape mutations in the F protein. RSV-A showed high genetic diversity with eleven circulating lineages, while RSV-B was dominated by lineage B.D.E.1. Phylogenetic analysis revealed three distinct B.D.4.1.1 groups, one sharing mutations with B.D.E.1 in the nirsevimab binding site. Despite these changes, neutralization assays confirmed that nirsevimab and other monoclonal antibodies remained effective. No significant antigenic drift compromising immunoprophylaxis was observed. These findings support the continued efficacy of nirsevimab and highlight the importance of genomic surveillance for tracking RSV evolution and informing future immunization strategies. María Iglesias-Caballero, Vicente Mas, Albert Campoy, Cristina Calvo, María Luz García, Sonia Alcolea, Laura Moreno-Parrado, Jordi Reina, Ana Navascués, Andrés Antón, Carlos Davina-Nunez, Sonia Perez-Castro, José Costa, Ana Fernández-González, José Antonio Lepe, Cristina Gaona, Zulema Pérez, Diego García-Martínez de Artola, Sonia Vázquez-Morón, Sara Camarero, Olga Cano, Francisco Pozo, Inmaculada Casas, Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration, The Journal of Infectious Diseases, Volume 233, Issue 2, 15 February 2026, Pages e409–e418, https://doi.org/10.1093/infdis/jiaf530. 10.1093/infdis/jiaf530 The Journal of Infectious Diseases https://hdl.handle.net/20.500.12105/27698 RELECOV Multicentre study RSV Genomic and antigenic surveillance Nirsevimab Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration.